EICHOR
● Not Yet Recruiting
Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
Condition: Parkinson's Disease (PD) · Parkinson Disease 6, Early-Onset · Sponsor: Hangzhou PhecdaMed Co., Ltd.
About this study
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients. This study plans to enroll approximately 300 EOPD participants, who will be randomized in a 1:1 ratio to two cohorts (Cohort 1: 200 mg dose group; Cohort 2: 400 mg dose group). Within each cohort, successfully screened participants will be stratified by stable use of dopamine receptor agonists (Yes vs. No) and stable use of Monoamine Oxidase B (MAO-B) inhibitors (Yes vs. No), and within each stratum, randomized in a 2:1 ratio to the TJ0113 Capsules group and the placebo group, with approximately 100 assigned to the TJ0113 Capsules group and approximately 50 assigned to the placebo group. In this trial, the sample size for the TJ0113 Capsules 200 mg group, TJ0113 Capsules 400 mg group, and placebo group will each be approximately 100 participants. After randomization, during the double-blind treatment period, participants will receive continuous oral administration of TJ0113 Capsules or placebo for 26 weeks. After the double-blind treatment ends, participants will enter the open-label treatment period. During the open-label treatment period, all participants will receive oral TJ0113 Capsules for 26 weeks, and the dose of TJ0113 Capsules will be consistent with the dose of the investigational product taken by the participant during the double-blind treatment period …
This description comes directly from the study's public registry record.
Talk to the study team
Dong Liu · +86-571-88779811 · dong.liu@phecdamed.com
Always discuss trial participation with your own doctor first.
Locations (21)
| Beijing Hospital | Beijing, Beijing Municipality, China | — |
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | — |
| Xuanwu Hospital, Capital Medical University | Beijing, Beijing Municipality, China | — |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | — |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | — |
| Henan Provincial People's Hospital | Zhengzhou, Henan, China | — |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | — |
| The Third Xiangya Hospital, Central South University | Changsha, Hunan, China | — |
| Xiangya Hospital, Central South University | Changsha, Hunan, China | — |
| General Hospital of Nuclear Industry (The Second Affiliated Hospital of Soochow University) | Suzhou, Jiangsu, China | — |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | — |
| West China Hospital, Sichuan University | Chengdu, Sichuan, China | — |
+ 9 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07741045